We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Novel Replacement Valve Offers Nonsurgical Aortic Valve Repair

By HospiMedica International staff writers
Posted on 14 Nov 2011
An innovative transcatheter heart valve (THV) offers a treatment option for patients too ill to undergo open-heart surgery for the repair of their calcified aortic valves.

The Sapien THV is intended for transcatheter aortic valve implantation (TAVI), and is based on a balloon expandable stainless steel frame with a polyethylene terephthalate (PET) skirt that encases bovine pericardial tissue leaflets, and is intended to be placed in the subcoronary position. More...


The tri-leaflet bovine pericardial prosthesis is treated with an anticalcification treatment, while the PET fabric skirt has been designed to decrease perivalvular leaks. The valve is available in two sizes (23 and 26 mm), treating an annulus range of 18 mm to 22 mm and 21 mm to 25 mm, respectively.

The system also includes the proprietary RetroFlex 3 delivery system, RetroFlex 3 introducer sheath set, RetroFlex dilator kit, and the RetroFlex balloon catheter, crimper, and Atrion inflation device. The RetroFlex Balloon Catheter is indicated for predilatation of a stenotic cardiac valve prior to implantation of the THV, while the Crimper is indicated for preparing the THV for implantation. The Sapien THV is a product of Edwards Lifesciences (Irvine, CA, USA), and has been approved by the US Food and Drug Administration (FDA), following the pivotal PARTNER trial.

In a quality of life (QOL) sub-study of the trial, 358 patients were assessed upon enrollment and at follow-up intervals of one month, six months, and 12 months, on a broad range of factors, such as their symptoms, physical and social limitations, and heart-failure related quality of life. On a scale from 0 to 100, the Edwards THV patients had a 25-point improvement in quality of life scores compared to the control group (at one year).

“The degree and immediacy of the quality of life improvement was striking, with significant benefits seen as early as one month. By one year, patients experienced both cardiovascular and physical health benefits, with the physical improvements roughly comparable to a 10-year reduction in age,” said David Cohen, MD, MSc, director of cardiovascular research at St. Luke's Mid America Heart and Vascular Institute (Kansas City, MO, USA), and principal investigator for the QOL substudy. “Quality of life is critically important, particularly for patients like those in this trial -- and they are not just surviving, but also thriving.”

Related Links:
Edwards Lifesciences
St. Luke's Mid America Heart and Vascular Institute


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
12-Channel ECG
CM1200B
New
VTE Prevention System
Flowtron ACS900
New
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The new device can detect molecules in air samples to diagnose a wide array of diseases (Photo courtesy of UChicago)

Breakthrough Portable Device Detects Airborne Viruses and Bacteria in Hospitals

For many years, detecting molecules in air has been significantly more challenging than detecting them in liquids. Despite the numerous medical advancements of the 20th century, the most reliable method... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.